Indira IVF

Indira IVF is an Indian fertility clinic chain that provides in assisted reproductive technology, including . Founded in 1988 by Dr. Ajay Murdia in Udaipur, Rajasthan, As of 2023, the company operated a network of over 150 centers across India.
The company, registered as Indira IVF Hospital Pvt. Ltd., provides fertility treatments. In 2023, private equity firm BPEA EQT acquired a majority stake.
History
Indira IVF was established in 1988 by Dr. Ajay Murdia in Udaipur, Rajasthan. By 2023, the company operated a network of over 150 centers across India.
In July 2023, BPEA EQT acquired a controlling stake in Indira IVF from TA Associates.
In January 2023, Bloomberg reported that Indira IVF's owners were considering a stake sale valuing the company at $1 billion, reflecting its growing market position in India's fertility sector.
Operations
Indira IVF provides a range of fertility treatments, including , , and , across its network of clinics in India.
The company reports the use of technologies such as Electronic Witnessing Systems, Closed Working Chambers Technology, Artificial Intelligence (AI) and Machine Learning, non-invasive pre-implantation genetic testing, and microfluidic sperm sorting techniques within its treatment protocols These technologies are reportedly intended to enhance the precision of fertility treatments.
Regulatory and Sector Engagement
Indira IVF has participated in Indian healthcare sector discussions through involvement in national policy. Dr. Nitiz Murdia was appointed to the National Assisted Reproductive Technology and Surrogacy Board, a government body overseeing reproductive technologies.
Dr. Ajay Murdia, the company's founder, has contributed to public discussions concerning infertility in India, addressing potential demographic implications. This involvement indicates the organization's participation in broader national discourses on reproductive health.
Indira IVF partnered with Safetree to introduce an infertility insurance plan.
The organization's operational activities include international expansion, as evidenced by the opening of a hospital in Kathmandu, Nepal. The company has announced plans to expand into child and maternal healthcare.
In the book 'Embryologist' (2021), Cüneyt Çetin highlights in his book the contributions of Indira IVF, including CEO and co-founder Kshitiz Murdia, to advancements in assisted reproductive technology, with a focus on genetic screening techniques like preimplantation genetic testing (PGT) and non-invasive preimplantation genetic testing (niPGT).

Main Menu

See Also

Main Menu